Pure Global AI
NCT06099769Recruiting

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

A RANDOMIZED, PHASE II STUDY OF ENZALUTAMIDE, ENZALUTAMIDE WITH MIFEPRISTONE, and TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH AR+ METASTATIC TRIPLE-NEGATIVE OR ER-LOW BREAST CANCER
Memorial Sloan Kettering Cancer CenterPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Metastatic Breast Cancer
Drug/Device/Intervention
Enzalutamide
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Memorial Sloan Kettering Cancer Center
Location
Birmingham,San Francisco,Chicago,Boston,New York,Chapel Hill, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Oct 18, 2023
End date
Oct 01, 2027
Enrollment
201 participants
Primary outcome

progression-free survival (PFS)

Summary

The researchers are doing this study to find out if the study drug, enzalutamide, alone or
 combined with the study drug, mifepristone, is effective in treating advanced or metastatic
 androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen
 receptor-low breast cancer (ER-low BC), and whether these study treatments work as well as
 standard chemotherapy with carboplatin, paclitaxel, capecitabine, or eribulin.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastMalignant neoplasm: Breast, unspecifiedMalignant neoplasm: Central portion of breastMalignant neoplasm: Overlapping lesion of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06099769
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06099769 through Pure Global AI's free database. This Phase 2 trial is sponsored by Memorial Sloan Kettering Cancer Center and is currently Recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 201 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.